Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCN
CUSIPN/A
Phone604-270-4344
Debt
Debt-to-Equity Ratio-0.73
Current Ratio0.92
Quick Ratio0.90
Price-To-Earnings
Trailing P/E Ratio-0.09
Forward P/E Ratio-0.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.39 million
Price / Sales10.35
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-0.07
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-22,900,000.00
Net Margins-1,687.90%
Return on Equity-85.81%
Return on Assets-52.15%
Miscellaneous
Employees147
Outstanding Shares1,860,190,000
Neovasc (NASDAQ:NVCN) Frequently Asked Questions
What is Neovasc's stock symbol?
Neovasc trades on the NASDAQ under the ticker symbol "NVCN."
How were Neovasc's earnings last quarter?
Neovasc Inc (NASDAQ:NVCN) issued its earnings results on Wednesday, March, 28th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The medical equipment provider had revenue of $1.23 million for the quarter, compared to the consensus estimate of $1.18 million. Neovasc had a negative return on equity of 85.81% and a negative net margin of 1,687.90%. View Neovasc's Earnings History.
When is Neovasc's next earnings date?
What price target have analysts set for NVCN?
2 equities research analysts have issued 12-month price objectives for Neovasc's shares. Their predictions range from $0.50 to $2.00. On average, they anticipate Neovasc's stock price to reach $1.25 in the next year. View Analyst Ratings for Neovasc.
Are investors shorting Neovasc?
Neovasc saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 97,894,894 shares, an increase of 34.2% from the May 15th total of 72,937,221 shares. Based on an average trading volume of 86,750,166 shares, the short-interest ratio is currently 1.1 days.
Who are some of Neovasc's key competitors?
Some companies that are related to Neovasc include SeaSpine (SPNE), Iradimed (IRMD), Apollo Endosurgery (APEN), Sensus Healthcare (SRTS), Motus GI (MOTS), Restoration Robotics (HAIR), Alphatec (ATEC), Invuity (IVTY), Invo Bioscience (IVOB), Arch Therapeutics (ARTH), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Hancock Jaffe Laboratories (HJLI), CAS Medical Systems (CASM) and Spectral Medical (EDTXF).
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Mr. Christopher Clark, CFO & Corp. Sec. (Age 46)
- Mr. Brian McPherson, Chief Operating Officer (Age 56)
- Ms. Vicki Bebeau, VP of Clinical and Regulatory Affairs
- Mr. Randy Lane, VP of R&D
- Mr. Alexei J. Marko, Advisor & Director (Age 49)
Has Neovasc been receiving favorable news coverage?
Media coverage about NVCN stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neovasc earned a news sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 46.07 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Neovasc's major shareholders?
Which institutional investors are buying Neovasc stock?
How do I buy shares of Neovasc?
Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neovasc's stock price today?
One share of NVCN stock can currently be purchased for approximately $0.03.
How big of a company is Neovasc?
Neovasc has a market capitalization of $62.69 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.
How can I contact Neovasc?
Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]
MarketBeat Community Rating for Neovasc (NVCN)
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
